<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f8f63d57-a207-4bd4-810f-7abd0fa2b73d"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use cysteine hydrochloride injection, USP safely and effectively.  See full prescribing information for cysteine hydrochloride injection, USP.<br/>
      <br/>
      <content styleCode="bold">Cysteine hydrochloride injection, USP, for intravenous use</content>
      <br/>Initial U.S. Approval: 1971</title>
   <effectiveTime value="20220429"/>
   <setId root="cbf70fc3-14b3-4c17-8de8-acba1e12ac95"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005083209" root="1.3.6.1.4.1.519.1"/>
            <name>Baxter Healthcare Corporation</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="6757921e-7f13-4192-8792-becfac4dc829"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20220429"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-9645" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CYSTEINE HYDROCHLORIDE</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>cysteine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="34.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="ZT934N0X4W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYSTEINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="K848JZ4886" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYSTEINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mL" value="0.006"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="5"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0338-9645-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220429"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA212535" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220429"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_0840027c-eee2-4683-a593-39e4ab132bca">
               <id root="0840027c-eee2-4683-a593-39e4ab132bca"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Cysteine hydrochloride injection, USP is indicated for use as an additive to amino acids solutions to meet nutritional requirements of neonates (preterm and term infants less than one month of age) requiring total parenteral nutrition.</paragraph>
               </text>
               <effectiveTime value="20220429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cysteine hydrochloride injection, USP is a sulfur-containing amino acid indicated for use as an additive to amino acids solutions to meet nutritional requirements of neonates (preterm and term infants less than one month of age) requiring total parenteral nutrition. (<linkHtml href="#ID_0840027c-eee2-4683-a593-39e4ab132bca">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_9e87f6cf-d9a1-4325-9582-1c3da6a46ecc">
               <id root="40f4b6cb-e33f-4741-8991-0ceedf61e772"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20220429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Cysteine hydrochloride injection, USP is for <content styleCode="italics">intravenous infusion after dilution and admixing</content> only. (<linkHtml href="#ID_a16df4f0-53a7-43f0-964f-db63a017899d">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>See full prescribing information for information on preparation, administration, and instructions for use. (<linkHtml href="#ID_a16df4f0-53a7-43f0-964f-db63a017899d">2.1</linkHtml>, <linkHtml href="#ID_23b6db3e-e80d-43a6-9439-b31d4d1b7a01">2.2</linkHtml>, <linkHtml href="#ID_b8f68636-179a-41ec-845c-190db1f49110">2.3</linkHtml>, <linkHtml href="#ID_e3dfa638-b27e-48ac-a6ec-7da98f4205dc">2.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>The recommended dosage in neonates is based upon the recommended daily protein (amino acid) requirements:  22 mg cysteine hydrochloride injection, USP/g amino acids.  The corresponding volume is 0.44 mL cysteine hydrochloride injection, USP/g amino acids. (<linkHtml href="#ID_89fc6513-d32a-4643-8b94-b14a3b41b6da">2.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_a16df4f0-53a7-43f0-964f-db63a017899d">
                     <id root="a16df4f0-53a7-43f0-964f-db63a017899d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration Information </title>
                     <text>
                        <paragraph>Cysteine hydrochloride injection, USP is for <content styleCode="italics">intravenous infusion after dilution and admixing use</content> only.  Prior to administration, cysteine hydrochloride injection, USP <content styleCode="italics">must be diluted and used as an admixture</content> in parenteral nutrition solutions.</paragraph>
                        <paragraph>The resulting solution is for intravenous infusion into a central or peripheral vein. The choice of a central or peripheral venous route should depend on the osmolarity of the final infusate. Solutions with osmolarity of 900 mOsm/L or greater must be infused through a central catheter [see <linkHtml href="#ID_3ccbd698-4f50-4004-8eb0-be1686809c3f">Warnings and Precautions (5.2)</linkHtml>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_23b6db3e-e80d-43a6-9439-b31d4d1b7a01">
                     <id root="23b6db3e-e80d-43a6-9439-b31d4d1b7a01"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Preparation and Administration Information </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Prior to administration, cysteine hydrochloride injection, USP <content styleCode="italics">must be diluted and used as an admixture</content> in parenteral nutrition solutions.</item>
                           <item>
                              <caption>•</caption>Cysteine hydrochloride injection, USP is to be prepared only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). The key factor in the preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and addition of other nutrients.</item>
                           <item>
                              <caption>•</caption>Cysteine hydrochloride injection, USP is for addition to amino acid solutions prior to further admixing with dextrose injection using a parenteral nutrition container.</item>
                           <item>
                              <caption>•</caption>Calcium and phosphate ratios must be considered. Excess addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of calcium phosphate precipitates [see <linkHtml href="#ID_f104719c-8215-4ca3-9125-477fb337bf0f">Warnings and Precautions (5.1)</linkHtml>]<content styleCode="italics">.</content>
                           </item>
                           <item>
                              <caption>•</caption>Use a dedicated line for parenteral nutrition solutions.</item>
                           <item>
                              <caption>•</caption>Intravenous lipid emulsions can be infused concurrently into the same vein as cysteine hydrochloride injection, USP-containing amino acid and dextrose solutions by a Y-connector located near the infusion site; flow rates of each solution should be controlled separately by infusion pumps.</item>
                           <item>
                              <caption>•</caption>For administration, use a 0.22 micron in-line filter.</item>
                           <item>
                              <caption>•</caption>To prevent air embolism, use a non-vented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible containers in series, fully evacuate residual gas in the container prior to administration, do not pressurize the flexible container to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the container runs dry.</item>
                           <item>
                              <caption>•</caption>Visually inspect the diluted parenteral nutrition solution containing cysteine hydrochloride injection, USP for particulate matter and discoloration before admixing, after admixing, after removal from refrigeration, and prior to administration. The solution should be clear and there should be no precipitates. A slight yellow color does not alter the quality and efficacy of this product.</item>
                        </list>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b8f68636-179a-41ec-845c-190db1f49110">
                     <id root="b8f68636-179a-41ec-845c-190db1f49110"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Preparation Instructions for Admixing Using a Parenteral Nutrition Container </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Remove cysteine hydrochloride injection, USP vial from the carton and inspect for particulate matter.</item>
                           <item>
                              <caption>•</caption>Transfer the required amount of cysteine hydrochloride injection, USP to an amino acid solution using strict aseptic techniques to avoid microbial contamination.</item>
                           <item>
                              <caption>•</caption>The amino acid solution containing cysteine hydrochloride injection, USP can then be used to prepare admixtures in the parenteral nutrition container using strict aseptic techniques.</item>
                           <item>
                              <caption>•</caption>Amino acids solution containing cysteine hydrochloride injection, USP may be mixed with dextrose injection. The following proper mixing sequence must be followed to minimize pH related problems:<list listType="unordered">
                                 <item>
                                    <caption>1.</caption>Transfer dextrose injection to the parental nutrition pooling container</item>
                                 <item>
                                    <caption>2.</caption>Transfer phosphate salt</item>
                                 <item>
                                    <caption>3.</caption>Transfer cysteine hydrochloride injection, USP-containing amino acid solution</item>
                                 <item>
                                    <caption>4.</caption>Transfer electrolytes</item>
                                 <item>
                                    <caption>5.</caption>Transfer trace elements</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>Use gentle agitation during admixing to minimize localized concentration effects; shake containers gently after each addition.</item>
                           <item>
                              <caption>•</caption>For automated compounding, refer to Instructions for Use of the applicable compounder.</item>
                           <item>
                              <caption>•</caption>Because additives may be incompatible, evaluate all additions to the parenteral nutrition container for compatibility and stability of the resulting preparation. Consult with pharmacist, if available. Questions about compatibility may be directed to Baxter Healthcare Corporation. If it is deemed advisable to introduce additives to the parenteral nutrition container, use aseptic technique.</item>
                           <item>
                              <caption>•</caption>Inspect the final parenteral nutrition solution containing cysteine hydrochloride injection, USP to ensure that precipitates have not formed during mixing or on addition of additives.  Discard if any precipitates are observed.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Stability and Storage</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>For single use only. Discard unused portion of the vial of cysteine hydrochloride injection, USP.</item>
                           <item>
                              <caption>•</caption>Use parenteral nutrition solution containing cysteine hydrochloride injection, USP promptly after mixing. Any storage of the admixture should be under refrigeration at 2ºC to 8ºC (36ºF to 46ºF) and limited to a brief period of time, no longer than 24 hours. After removal from refrigeration, inspect for precipitates, use promptly, and complete the infusion within 24 hours. Discard if any precipitates are observed.</item>
                           <item>
                              <caption>•</caption>Discard any remaining admixture.</item>
                           <item>
                              <caption>•</caption>Protect parenteral nutrition solution from light.</item>
                        </list>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e3dfa638-b27e-48ac-a6ec-7da98f4205dc">
                     <id root="76475fea-5648-46d0-93ff-370a702cbd16"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosing Considerations </title>
                     <text>
                        <paragraph>The dosage of the final parenteral nutrition solution containing cysteine hydrochloride injection, USP must be based on the concentrations of all components in the solution and the recommended nutritional requirements [see <linkHtml href="#ID_89fc6513-d32a-4643-8b94-b14a3b41b6da">Dosage and Administration (2.5)</linkHtml>]. Consult the prescribing information of all added components to determine the recommended nutritional requirements.</paragraph>
                        <paragraph>The dosage of cysteine hydrochloride injection, USP should be individualized based on the patient’s clinical condition (ability to adequately metabolize amino acids), body weight and nutritional/fluid requirements, as well as additional energy given orally/enterally to the patient. Prior to initiating parenteral nutrition, the following patient information should be reviewed: review of all medications, gastrointestinal function and laboratory data (such as electrolytes (including magnesium, calcium, and phosphorus), glucose, urea/creatinine, liver panel, and complete blood count.</paragraph>
                        <paragraph>Prior to administration of parenteral nutrition solution containing cysteine hydrochloride injection, USP, correct severe fluid, electrolyte and acid-base disorders.</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_89fc6513-d32a-4643-8b94-b14a3b41b6da">
                     <id root="813b0f71-d64c-4f4a-9d42-c1f0e8339c44"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Recommended Dosage for Neonates </title>
                     <text>
                        <paragraph>The recommended dosage and volume of cysteine hydrochloride injection, USP is based upon the recommended daily protein (amino acid) requirements.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1. Recommended Daily Dosage of cysteine hydrochloride injection, USP in Neonates (Preterm and Term Infants Less Than One Month of Age)</content>
                        </paragraph>
                        <table width="100%">
                           <col width="11%"/>
                           <col width="26%"/>
                           <col width="32%"/>
                           <col width="32%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Protein</content>
                                       <footnote ID="_Ref101879209">Protein is provided as amino acids.</footnote>
                                       <content styleCode="bold"> Requirement <br/>(g Amino Acids/kg/day)<sup>1</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Dosage<br/>(mg cysteine hydrochloride injection, USP/g Amino Acids)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Volume <br/>(mL cysteine hydrochloride injection, USP/g Amino Acids)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Neonates</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>3 to 4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>0.44</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                           </item>
                        </list>
                        <paragraph>Cysteine hydrochloride injection, USP contains 50 mg/mL of cysteine hydrochloride (equivalent to 34.5 mg/mL of cysteine). Therefore, the recommended dosage of cysteine hydrochloride injection, USP provides 15 mg cysteine/gram of amino acids for neonates.</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_dab81094-3388-41fe-8374-2b6d4b074647">
               <id root="dab81094-3388-41fe-8374-2b6d4b074647"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Injection:  500 mg/10 mL (50 mg/mL) cysteine hydrochloride, USP as a clear, colorless, sterile solution in a single-dose vial.</paragraph>
               </text>
               <effectiveTime value="20220429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection:  500 mg/10 mL (50 mg/mL) cysteine hydrochloride, USP in a single-dose vial. (<linkHtml href="#ID_dab81094-3388-41fe-8374-2b6d4b074647">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_c2a04396-7282-462f-805d-78b205ef2cad">
               <id root="c2a04396-7282-462f-805d-78b205ef2cad"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Cysteine hydrochloride injection, USP is contraindicated in:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Patients with known hypersensitivity to one or more amino acids.</item>
                     <item>
                        <caption>•</caption>Patients with inborn errors of amino acid metabolism due to risk of severe metabolic or neurologic complications.</item>
                     <item>
                        <caption>•</caption>Patients with pulmonary edema or acidosis due to low cardiac output.</item>
                  </list>
               </text>
               <effectiveTime value="20220429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hypersensitivity to one or more amino acids (<linkHtml href="#ID_c2a04396-7282-462f-805d-78b205ef2cad">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Inborn errors of amino acid metabolism (<linkHtml href="#ID_c2a04396-7282-462f-805d-78b205ef2cad">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Pulmonary edema or acidosis due to low cardiac output (<linkHtml href="#ID_c2a04396-7282-462f-805d-78b205ef2cad">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_f3365a69-372f-4834-9246-deea93762082">
               <id root="a6ca8d56-3fe2-4b5a-9342-c33fb702a470"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20220429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Pulmonary Embolism due to Pulmonary Vascular Precipitates</content>: If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. (<linkHtml href="#ID_f104719c-8215-4ca3-9125-477fb337bf0f">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Vein Damage and Thrombosis</content>: Solutions with osmolarity of 900 mOsm/L or more must be infused through a central catheter (<linkHtml href="#ID_a16df4f0-53a7-43f0-964f-db63a017899d">2.1</linkHtml>, <linkHtml href="#ID_3ccbd698-4f50-4004-8eb0-be1686809c3f">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Increased Blood Urea Nitrogen (BUN)</content>: Monitor laboratory parameters and discontinue if BUN exceeds normal postprandial limits and continues to increase. (<linkHtml href="#ID_f5f61d90-1105-4ad8-807c-365e2d724845">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Acid-Base Imbalance</content>: Monitor laboratory parameters and supplement with electrolytes as needed. (<linkHtml href="#ID_5577c44a-3a75-48f3-8155-a04f0be50c81">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Hepatobiliary Disorders</content>: Neurocognitive delay possible in infants; monitor liver function parameters and ammonia levels. (<linkHtml href="#ID_57f744d5-53b5-471b-b14f-f318e9d90455">5.5</linkHtml>, <linkHtml href="#ID_1e574a86-b554-4fcf-9a8a-576a88d04b1e">8.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Aluminum Toxicity</content>: Increased risk in patients with renal impairment, including preterm infants. (<linkHtml href="#ID_7a6b1887-e332-4686-a267-2703fb24f38e">5.6</linkHtml>, <linkHtml href="#ID_1e574a86-b554-4fcf-9a8a-576a88d04b1e">8.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Monitoring and Laboratory Tests</content>: Monitor fluid and electrolytes, serum osmolarity, blood glucose, kidney and liver function, blood count, and coagulation parameters throughout treatment. (<linkHtml href="#ID_326b00b7-57aa-4fe3-b4fa-8f765e776692">5.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_f104719c-8215-4ca3-9125-477fb337bf0f">
                     <id root="f104719c-8215-4ca3-9125-477fb337bf0f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Pulmonary Embolism due to Pulmonary Vascular Precipitates </title>
                     <text>
                        <paragraph>Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition. In some fatal cases, pulmonary embolism occurred as a result of calcium phosphate precipitates. Precipitation following passage through an in-line filter and suspected in vivo precipitate formation has also been reported. If signs of pulmonary distress occur, stop the parenteral nutrition infusion and initiate a medical evaluation. In addition to inspection of the solution [see <linkHtml href="#ID_a16df4f0-53a7-43f0-964f-db63a017899d">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_23b6db3e-e80d-43a6-9439-b31d4d1b7a01">2.2)</linkHtml>], the infusion set and catheter should also periodically be checked for precipitates.</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3ccbd698-4f50-4004-8eb0-be1686809c3f">
                     <id root="3ccbd698-4f50-4004-8eb0-be1686809c3f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Vein Damage and Thrombosis </title>
                     <text>
                        <paragraph>Cysteine hydrochloride injection, USP must be diluted and used as an admixture in parenteral nutrition solutions. Solutions with an osmolarity of 900 mOsm/L or greater must be infused through a central catheter [see <linkHtml href="#ID_a16df4f0-53a7-43f0-964f-db63a017899d">Dosage and Administration (2.1)</linkHtml>]. The infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f5f61d90-1105-4ad8-807c-365e2d724845">
                     <id root="f5f61d90-1105-4ad8-807c-365e2d724845"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Increased Blood Urea Nitrogen (BUN) </title>
                     <text>
                        <paragraph>Intravenous infusion of amino acids may induce a rise in blood urea nitrogen (BUN), especially in patients with impaired hepatic or renal function. Appropriate laboratory tests should be performed periodically and infusion discontinued if BUN levels exceed normal postprandial limits and continue to rise. It should be noted that a modest rise in BUN normally occurs as a result of increased protein intake.</paragraph>
                        <paragraph>Administration of amino acid solutions in the presence of impaired renal function may augment an increasing BUN, as does any protein dietary component.</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5577c44a-3a75-48f3-8155-a04f0be50c81">
                     <id root="5577c44a-3a75-48f3-8155-a04f0be50c81"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Acid-Base Imbalance </title>
                     <text>
                        <paragraph>Administration of cysteine hydrochloride injection, USP may result in metabolic acidosis in neonates.</paragraph>
                        <paragraph>Administration of amino acid solutions to a patient with hepatic impairment may result in serum amino acid imbalances, metabolic alkalosis, prerenal azotemia, hyperammonemia, stupor and coma.</paragraph>
                        <paragraph>Frequent clinical evaluation and laboratory determinations are necessary for proper monitoring of acid-base balance during parenteral nutrition therapy. Significant deviations from normal concentrations may require the use of additional electrolyte supplements.</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_57f744d5-53b5-471b-b14f-f318e9d90455">
                     <id root="57f744d5-53b5-471b-b14f-f318e9d90455"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hepatobiliary Disorders </title>
                     <text>
                        <paragraph>Hepatobiliary disorders are known to develop in some patients, including neonates, without preexisting liver disease who receive parenteral nutrition, including cholecystitis, cholelithiasis, cholestasis, hepatic steatosis, fibrosis and cirrhosis, possibly leading to hepatic failure. The etiology of these disorders is thought to be multifactorial and may differ between patients.</paragraph>
                        <paragraph>Instances of asymptomatic hyperammonemia have been reported in patients receiving parenteral nutrition without overt liver dysfunction. The mechanisms of this reaction are not clearly defined but may involve genetic defects and immature or subclinically impaired liver function [see <linkHtml href="#ID_c2a04396-7282-462f-805d-78b205ef2cad">Contraindications (4)</linkHtml>, <linkHtml href="#ID_1e574a86-b554-4fcf-9a8a-576a88d04b1e">Use in Specific Populations (8.4)</linkHtml>]</paragraph>
                        <paragraph>Hyperammonemia is of special significance in infants, as it can result in neurocognitive delays. Monitor liver function parameters and ammonia levels during treatment with cysteine hydrochloride injection, USP. Patients developing signs of hepatobiliary disorders should be assessed early by a clinician knowledgeable in liver diseases in order to identify possible causative and contributory factors, and possible therapeutic and prophylactic interventions.</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7a6b1887-e332-4686-a267-2703fb24f38e">
                     <id root="285f1d92-deae-4f45-8fc2-99cd96f5bb64"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Aluminum Toxicity </title>
                     <text>
                        <paragraph>Cysteine hydrochloride injection, USP contains aluminum that may be toxic.</paragraph>
                        <paragraph>Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impairment. Neonates and preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which also contain aluminum.</paragraph>
                        <paragraph>Patients with renal impairment including neonates and preterm infants, who receive greater than 4 to 5 mcg/kg/day of parenteral aluminum can accumulate aluminum to levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.</paragraph>
                        <paragraph>Exposure to aluminum from cysteine hydrochloride injection, USP is not more than 0.25 mcg/kg/day when preterm and term neonates are administered the recommended maximum dosage of cysteine hydrochloride injection, USP (22 mg cysteine hydrochloride/g of amino acids and 4 g of amino acids/kg/day) [see <linkHtml href="#ID_89fc6513-d32a-4643-8b94-b14a3b41b6da">Dosage and Administration (2.5)</linkHtml>]. When prescribing cysteine hydrochloride injection, USP for use in parenteral nutrition containing other small volume parenteral products, the total daily patient exposure to aluminum from the admixture should be considered and maintained at no more than 5 mcg/kg/day [see <linkHtml href="#ID_1e574a86-b554-4fcf-9a8a-576a88d04b1e">Use in Specific Populations (8.4)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_326b00b7-57aa-4fe3-b4fa-8f765e776692">
                     <id root="939624de-6e1e-4d39-bff3-80e3138390f0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Monitoring and Laboratory Tests </title>
                     <text>
                        <paragraph>Monitor fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, ammonia levels, blood count and coagulation parameters throughout treatment [see <linkHtml href="#ID_e3dfa638-b27e-48ac-a6ec-7da98f4205dc">Dosage and Administration (2.4)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4edfb12f-58ff-47b1-8f9f-d9986ec27c40">
               <id root="43ba480d-b5f5-4947-adb6-bbc3f38c652e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Pulmonary embolism due to pulmonary vascular precipitates [see <linkHtml href="#ID_f104719c-8215-4ca3-9125-477fb337bf0f">Warnings and Precautions (5.1)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Vein damage and thrombosis [see <linkHtml href="#ID_3ccbd698-4f50-4004-8eb0-be1686809c3f">Warnings and Precautions (5.2)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Increased BUN [see <linkHtml href="#ID_f5f61d90-1105-4ad8-807c-365e2d724845">Warnings and Precautions (5.3)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Acid-base imbalance [see <linkHtml href="#ID_5577c44a-3a75-48f3-8155-a04f0be50c81">Warnings and Precautions (5.4)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Hepatobiliary disorders [see <linkHtml href="#ID_57f744d5-53b5-471b-b14f-f318e9d90455">Warning and Precautions (5.5)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Aluminum toxicity [see <linkHtml href="#ID_7a6b1887-e332-4686-a267-2703fb24f38e">Warnings and Precautions (5.6)</linkHtml>]</item>
                  </list>
                  <paragraph>Adverse reactions with the use of cysteine hydrochloride injection were identified in clinical studies or postmarketing reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Metabolic acidosis</item>
                     <item>
                        <caption>•</caption>Local infusion site reactions, including a warm sensation, erythema, phlebitis, and thrombosis at the infusion site</item>
                     <item>
                        <caption>•</caption>Generalized flushing, fever, and nausea</item>
                  </list>
               </text>
               <effectiveTime value="20220429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are local reactions (warm sensation, erythema, phlebitis, and thrombosis at the infusion site), generalized flushing, fever, nausea, and metabolic acidosis. (<linkHtml href="#ID_4edfb12f-58ff-47b1-8f9f-d9986ec27c40">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Baxter Healthcare Corporation at 1-866-888-2472</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_22c76223-4882-4951-947e-1da92a544c79">
               <id root="22c76223-4882-4951-947e-1da92a544c79"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20220429"/>
               <component>
                  <section ID="ID_28028bbf-e8f5-4a3a-a4a1-e6dd98116905">
                     <id root="28028bbf-e8f5-4a3a-a4a1-e6dd98116905"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Cysteine hydrochloride injection, USP for use as an additive to amino acid solutions to meet nutritional requirements is not indicated for use in adults. Appropriate administration of cysteine hydrochloride injection, USP is not expected to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with cysteine hydrochloride.</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d86aad37-ea78-45f5-8f0f-e8e6ab3f062a">
                     <id root="d86aad37-ea78-45f5-8f0f-e8e6ab3f062a"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Cysteine hydrochloride injection, USP is used as an additive to amino acid solutions to meet nutritional requirements of neonates requiring total parenteral nutrition and is not indicated for use in adults. There are no data on the presence of cysteine hydrochloride in human or animal milk or the effects on milk production. Data available on the effects of cysteine hydrochloride on infants, either directly or through breastmilk, do not suggest a significant risk of adverse reactions from exposure.</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1e574a86-b554-4fcf-9a8a-576a88d04b1e">
                     <id root="1e574a86-b554-4fcf-9a8a-576a88d04b1e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Cysteine hydrochloride injection, USP is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of neonates, including preterm infants, requiring total parenteral nutrition. The safety profile for cysteine hydrochloride injection, USP use in neonates includes risks of acid-base imbalance and hepatobiliary dysfunction.</paragraph>
                        <paragraph>Acid-base imbalance, including metabolic acidosis, and liver dysfunction may occur with cysteine hydrochloride injection, USP administration in preterm infants. Frequent clinical and laboratory assessments are necessary to monitor and manage fluid balance, electrolyte concentrations, liver tests, and acid-base balance during parenteral nutrition therapy [see <linkHtml href="#ID_5577c44a-3a75-48f3-8155-a04f0be50c81">Warnings and Precautions (5.4)</linkHtml>]<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>Hyperammonemia is of special significance in neonates. This reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. It is essential that blood ammonia be measured during treatment [see <linkHtml href="#ID_57f744d5-53b5-471b-b14f-f318e9d90455">Warnings and Precautions (5.5)</linkHtml>]<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>Because of immature renal function, neonates including preterm infants, receiving prolonged parenteral nutrition with cysteine hydrochloride injection, USP may be at higher risk of aluminum toxicity [see <linkHtml href="#ID_326b00b7-57aa-4fe3-b4fa-8f765e776692">Warnings and Precautions (5.7)</linkHtml>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4f9665bb-1f1f-441b-a301-61d123f80af3">
               <id root="4f9665bb-1f1f-441b-a301-61d123f80af3"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>In the event of over hydration or solute overload, re-evaluate the patient and institute appropriate corrective measures [see <linkHtml href="#ID_f5f61d90-1105-4ad8-807c-365e2d724845">Warnings and Precautions (5.3</linkHtml>, <linkHtml href="#ID_5577c44a-3a75-48f3-8155-a04f0be50c81">5.4</linkHtml>, <linkHtml href="#ID_57f744d5-53b5-471b-b14f-f318e9d90455">5.5</linkHtml>, <linkHtml href="#ID_326b00b7-57aa-4fe3-b4fa-8f765e776692">5.7</linkHtml>)].</paragraph>
               </text>
               <effectiveTime value="20220429"/>
            </section>
         </component>
         <component>
            <section ID="ID_cb386050-b902-4a80-bad7-1402f103ada0">
               <id root="cb386050-b902-4a80-bad7-1402f103ada0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Cysteine hydrochloride injection, USP (cysteine hydrochloride injection) is a sterile, nonpyrogenic solution for intravenous use supplied as 500 mg/10 mL cysteine hydrochloride, USP in a single-dose vial.</paragraph>
                  <paragraph>Each mL of cysteine hydrochloride injection, USP contains 50 mg of cysteine hydrochloride, (equivalent to 34.5 mg of cysteine), and 0.006 mL of hydrochloric acid (6M) in water for injection. Sodium hydroxide and/or hydrochloric acid are used as needed to adjust the pH. The pH range of cysteine hydrochloride injection, USP is 1.0 to 1.5.</paragraph>
                  <paragraph>The active ingredient is cysteine hydrochloride. The chemical name of cysteine hydrochloride is L-cysteine hydrochloride monohydrate. Its molecular formula is C<sub>3</sub>H<sub>7</sub>NO<sub>2</sub>S • HCI • H<sub>2</sub>O and molecular weight is 175.63. The chemical structure of L-cysteine hydrochloride monohydrate is depicted below:</paragraph>
                  <renderMultiMedia ID="id554281535" referencedObject="a90721a9-9195-4346-8375-b7ac7ab86f76"/>
                  <paragraph>Cysteine hydrochloride is a white crystalline powder soluble in water. Cysteine is a sulfur-containing amino acid and is prone to oxidation when exposed to air in aqueous solution, which may convert cysteine to insoluble cystine resulting in precipitation over time.</paragraph>
                  <paragraph>Cysteine hydrochloride injection, USP contains no more than 145 mcg/L of aluminum.</paragraph>
               </text>
               <effectiveTime value="20220429"/>
               <component>
                  <observationMedia ID="a90721a9-9195-4346-8375-b7ac7ab86f76">
                     <text>Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_d2521100-9b12-4281-8c7f-248fc3948a9e">
               <id root="d2521100-9b12-4281-8c7f-248fc3948a9e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20220429"/>
               <component>
                  <section ID="ID_15a73927-a0ab-4b37-abd7-b2ef66ba68bb">
                     <id root="15a73927-a0ab-4b37-abd7-b2ef66ba68bb"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Endogenous cysteine is synthesized from methionine by the enzyme, cystathionase, via the trans-sulfuration pathway, and serves as a precursor substrate for both glutathione and taurine. Cysteine hydrochloride injection, USP provides cysteine to the systemic circulation of neonates who require parenteral nutrition and cannot synthesize adequate quantities of cysteine due to deficient cystathionase activity.</paragraph>
                     </text>
                     <effectiveTime value="20220429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e46f2f98-a2b7-463c-a690-deed6d4ab0f8">
               <id root="e46f2f98-a2b7-463c-a690-deed6d4ab0f8"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES </title>
               <text>
                  <paragraph>1. Ayers P. et al. A.S.P.E.N. Parenteral Nutrition Handbook, 2nd ed. 2014 pg. 123 and 124.</paragraph>
               </text>
               <effectiveTime value="20220429"/>
            </section>
         </component>
         <component>
            <section ID="ID_d1457b28-e398-4e29-9131-2195f72727d1">
               <id root="d1457b28-e398-4e29-9131-2195f72727d1"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Cysteine hydrochloride injection, USP (cysteine hydrochloride injection) is a clear, colorless, sterile and nonpyrogenic solution supplied as follows:</paragraph>
                  <paragraph>500 mg/10 mL (50 mg/mL) of cysteine hydrochloride, USP in single-dose vials (NDC  0338-<br/>9645-01), packaged as 5 vials per carton (NDC 0338-9645-01)</paragraph>
                  <paragraph>Store cysteine hydrochloride injection, USP at 20°C to 25°C (68°F to 77°F); excursions<br/>permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Protect from light. Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard<br/>the vial.</paragraph>
                  <paragraph>Vial stoppers are not made with natural rubber latex.</paragraph>
                  <paragraph>For storage of admixed solution see <content styleCode="italics">Dosage and Administration (2.3)</content>
                  </paragraph>
               </text>
               <effectiveTime value="20220429"/>
            </section>
         </component>
         <component>
            <section ID="ID_bb607eee-c322-4b92-a2b6-8d6f9d8de24d">
               <id root="3883a238-fb70-4e95-a99f-f83b7df5fb90"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Inform caregivers or home healthcare providers of the following risks of cysteine hydrochloride injection, USP:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Pulmonary embolism due to pulmonary vascular precipitates [see <linkHtml href="#ID_f104719c-8215-4ca3-9125-477fb337bf0f">Warnings and Precautions (5.1)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Vein damage and thrombosis [see <linkHtml href="#ID_3ccbd698-4f50-4004-8eb0-be1686809c3f">Warnings and Precautions (5.2)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Increased BUN [see <linkHtml href="#ID_f5f61d90-1105-4ad8-807c-365e2d724845">Warnings and Precautions (5.3)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Acid-base imbalance [see <linkHtml href="#ID_5577c44a-3a75-48f3-8155-a04f0be50c81">Warnings and Precautions (5.4)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Hepatobiliary disorders [see <linkHtml href="#ID_57f744d5-53b5-471b-b14f-f318e9d90455">Warning and Precautions (5.5)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Aluminum toxicity [see <linkHtml href="#ID_7a6b1887-e332-4686-a267-2703fb24f38e">Warnings and Precautions (5.6)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Monitoring and laboratory tests [see <linkHtml href="#ID_326b00b7-57aa-4fe3-b4fa-8f765e776692">Warnings and Precautions (5.7)</linkHtml>]</item>
                  </list>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Baxter Healthcare Corporation,</paragraph>
                  <paragraph>Deerfield, IL 60015, USA</paragraph>
                  <paragraph>Baxter is a registered trademark of Baxter International Inc.</paragraph>
                  <paragraph>Rev.  04/22</paragraph>
                  <paragraph>07-19-00-4043</paragraph>
               </text>
               <effectiveTime value="20220429"/>
            </section>
         </component>
         <component>
            <section ID="ID_b3d4e29b-f49e-4845-8e70-19c47c15b7f0">
               <id root="2118b8ac-644f-4a10-8e76-7a35a42f0c0f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <renderMultiMedia ID="id1807969882" referencedObject="ID_5db98821-2940-477a-917c-805373ecab0d"/>
                  <paragraph>NDC 0338-9645-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cysteine hydrochloride injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg/10 mL (50 mg/mL)</content>
                  </paragraph>
                  <paragraph>Must be Diluted. For Intravenous <br/>Infusion Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile</content>
                  </paragraph>
                  <paragraph>10 mL Single-Dose Vial <br/>Discard Unused Portion</paragraph>
                  <paragraph>
                     <content styleCode="bold">Each mL contains:</content> 50 mg cysteine hydrochloride<br/>(equivalent to 34.5 mg of cysteine), and 0.006 mL<br/>of hydrochloric acid (6M) in water for injection.<br/>Sodium hydroxide and/or hydrochloric acid are<br/>used as needed to adjust the pH to 1.0 to 1.5.<br/>Contains no more than 145 mcg/l of aluminum.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content> Store at 20°C to 25°C (68°F to <br/>77°F ), excursions permitted to 15° to 30°C<br/>(59°F to 86°F) [see USP Controlled Room<br/>Temperature]. Do not freeze.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Recommended Dosage:<br/>
                     </content>See prescribing information.<br/>Mfd. for Baxter Healthcare Corp</paragraph>
                  <paragraph>Rev 03/22</paragraph>
                  <paragraph>07-09-00-1048</paragraph>
                  <paragraph>For Position Box Only</paragraph>
                  <paragraph>LOT: XXXXXX<br/>EXP: YYYY-MM-DD</paragraph>
                  <renderMultiMedia ID="id1648937814" referencedObject="ID_6aabe06c-3899-437a-b360-2c3e4eec407b"/>
                  <paragraph>NDC 0338-9645-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cysteine hydrochloride injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg/10 mL (50 mg/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Must be Diluted. For Intravenous Infusion Only<br/>
                     </content>
                  </paragraph>
                  <paragraph>5 x 10 mL Single-Dose Vials – Discard Unused Portion</paragraph>
                  <paragraph>Reserved for 2D barcode</paragraph>
                  <paragraph>GTIN XXXXXXXXXXXXXX<br/>SN XXXXXXXXXXXXXX<br/>LOT XXXXXX<br/>EXP YYY-MD-DD</paragraph>
                  <paragraph>NDC 0338-9645-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cysteine hydrochloride injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg/10 mL (50 mg/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Must be Diluted. For Intravenous Infusion Only<br/>
                     </content>Contains no more than 145 mcg/L of aluminum</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile</content>
                  </paragraph>
                  <paragraph>5 x 10 mL Single-Dose Vials – Discard Unused Portion</paragraph>
                  <paragraph>07-03-00-0794</paragraph>
                  <paragraph>
                     <content styleCode="bold">Each mL of cysteine hydrochloride injection, USP<br/>contains:</content> 50mg of cysteine hydrochloride (equivalent<br/>to 34.5 mg of cysteine), and 0.006 mL of hydrochloric<br/>acid (6M) in water for injection. Sodium hydroxide or<br/>hydrochloric acid are used as needed to adjust the<br/>pH. The pH range is 1.0 to 1.5.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content> Store at 20°C to 25°C (68°F to 77°F ),<br/>excursions permitted to 15°C to 30°C (59°F to 86°F )<br/>[see USP Controlled Room Temperature]. Protect<br/>from light. Avoid excessive heat. Protect from<br/>freezing. If accidently frozen, discard the vial.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Directions for Use:</content> For single use only. Discard<br/>unused portion of the vial of cysteine hydrochloride<br/>injection, USP. Use parenteral nutrition solution<br/>containing cysteine hydrochloride injection, USP<br/>promptly after mixing. Any storage of the<br/>admixture should be under refrigeration at 2°C to<br/>8°C (36°F to 46°F) and limited to brief period of<br/>time, no longer than 24 hours. After removal from<br/>refrigeration, inspect for precipitates, use<br/>promptly, and complete the infusion within 24<br/>hours. Discard if any precipitates are observed.<br/>Discard any remaining admixture. Protect<br/>parenteral nutrition solution from light.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Recommended Dosage:</content>
                     <br/>See prescribing information.</paragraph>
                  <paragraph>NDC 0338-9645-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Cysteine hydrochloride injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg/10 mL (50 mg/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Must be Diluted. For Intravenous Infusion Only<br/>
                     </content>Contains no more than 145 mcg/L of aluminum</paragraph>
                  <paragraph>5 x 10 mL Single-Dose Vials- Discard Unused Portion</paragraph>
                  <paragraph>For Position Only Box</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter</content>
                     </content>
                  </paragraph>
                  <paragraph>Baxter is a registered trademark<br/>of Baxter International Inc.<br/>Manufactured for<br/>Baxter Healthcare Corporation,<br/>Deerfield, IL 60015, USA</paragraph>
                  <paragraph>Rev 03/2022</paragraph>
               </text>
               <effectiveTime value="20220429"/>
               <component>
                  <observationMedia ID="ID_5db98821-2940-477a-917c-805373ecab0d">
                     <text>Representative Container Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_6aabe06c-3899-437a-b360-2c3e4eec407b">
                     <text>Representative Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>